Redefining Atopic Dermatitis Care: Monoclonal Antibody CM310 Offers Hope, with Dr. Jianzhong Zhang
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Redefining Atopic Dermatitis Care: Monoclonal Antibody CM310 Offers Hope, with Dr. Jianzhong Zhang
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Will the humanized monoclonal antibody CM310 transform treatment outcomes for patients with atopic dermatitis?
In this episode, we speak with Dr. Jianzhong Zhang, Professor at Peking University People’s Hospital, who introduces a breakthrough drug for atopic dermatitis called CM310 and discusses its potential to improve the quality of life for patients living with this chronic skin condition.
In 2024, Dr. Zhang and his collaborators published the results of a pivotal clinical trial evaluating the efficacy and safety of CM310. The article is titled, “Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.”
Guest: Dr. Jianzhong Zhang
Host: John L
Summary:
We explore the potential of a monoclonal antibody drug—named CM310—for treating atopic dermatitis, focusing on the results of a clinical trial conducted in China and published in the Chinese Medical Journal.